[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100545431":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":29,"centralContacts":33,"locations":38,"responsibleParty":56,"collaborators":58,"id":73,"slug":74,"hasResults":75,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":25,"eligibilityCriteria":79,"healthyVolunteers":75,"sex":80,"minAge":25,"maxAge":25,"enrollmentInfo":81,"targetDuration":25,"studyType":84,"phases":85,"briefSummary":87,"conditions":88,"keywords":25,"overallStatus":40,"whyStopped":25,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":101},{"fullName":5,"class":6},"The First Affiliated Hospital of Soochow University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Haplo-cord HCT","EXPERIMENTAL","Patients enrolled in this arm will receive a coinfusion of cord blood unit in addition to a typical haploidentical hematopoietic cell transplantation",[13],"Biological: Haplo-cord HCT",{"label":15,"type":16,"description":17,"interventionNames":18},"Haplo-HCT","ACTIVE_COMPARATOR","Patients enrolled in this arm will receive a typical haploidentical hematopoietic cell transplantation",[19],"Biological: Haplo-HCT",[21,26],{"type":22,"name":9,"description":23,"armGroupLabels":24,"otherNames":25},"BIOLOGICAL","Haploidentical hematopoietic cell transplantation will be performed with coinfusion of an unrelated cord blood unit",[9],null,{"type":22,"name":15,"description":27,"armGroupLabels":28,"otherNames":25},"Hematopoietic cell transplantation will be performed with a haploidentical donor",[15],[30],{"name":31,"affiliation":5,"role":32},"Yang XU","PRINCIPAL_INVESTIGATOR",[34],{"name":31,"role":35,"phone":36,"phoneExt":25,"email":37},"CONTACT","86+051267781850","xuyang1020@126.com",[39],{"facility":5,"status":40,"city":41,"state":42,"zip":43,"country":44,"countryCode":45,"cosmosGeoPoint":46,"geoPoint":51,"contacts":52},"RECRUITING","Suzhou","Jiangsu","215000","China","CN",{"type":47,"coordinates":48},"Point",[49,50],120.59538,31.30408,{"lat":50,"lon":49},[53,54],{"name":31,"role":35,"phone":36,"phoneExt":25,"email":37},{"name":55,"role":32,"phone":25,"phoneExt":25,"email":25},"Yang Xu",{"type":57,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR",[59,61,63,65,67,69,71],{"name":60,"class":6},"Children's Hospital of Soochow University",{"name":62,"class":6},"Ruijin Hospital",{"name":64,"class":6},"Nanfang Hospital, Southern Medical University",{"name":66,"class":6},"Fujian Medical University Union Hospital",{"name":68,"class":6},"First Affiliated Hospital Xi'an Jiaotong University",{"name":70,"class":6},"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology",{"name":72,"class":6},"Zhejiang University","100545431","phase-3-haplo-cord-hct-vs-haplo-hct-for-t-all-patients-100545431",false,"NCT06381817","Haplo-cord HCT vs. Haplo-HCT for T-ALL Patients","Haploidentical Hematopoietic Cell Transplantation Combined With an Unrelated Cord Blood Unit for Acute T Cell Lymphoblastic Leukemia Compared to Haploidentical Hematopoietic Cell Transplantation: a Multicenter, Randomized, Open-label Trial","Inclusion Criteria:\n\n* Patients with acute T cell lymphoblastic leukemia\n* With available minimal residual disease parameters assessed by flow cytometry and\u002For quantitative polymerase chain reaction\n* Willing to undergo haploidentical hematopoietic cell transplantation and having a suitable haploidentical donor\n* With Eastern Cooperative Oncology Group (ECOG) performance status of 0-3\n* Signing an informed consent form, having the ability to comply with study and follow-up procedures\n\nExclusion Criteria:\n\n* With other malignancies\n* Failing to acquire a suitable unrelated cord blood unit\n* With a previous history of autologous hematopoietic cell transplantation, allogeneic hematopoietic cell transplantation or chimeric antigen receptor T cell therapy\n* With uncontrolled infection intolerant to haploidentical hematopoietic cell transplantation\n* With severe organ dysfunction\n* In pregnancy or lactation period\n* With any conditions not suitable for the trial (investigators' decision)","ALL",{"count":82,"type":83},146,"ESTIMATED","INTERVENTIONAL",[86],"PHASE3","The goal of this clinical trial is to learn if haploidentical hematopoietic cell transplantation combined with an unrelated cord blood unit (haplo-cord HCT) works to treat acute T cell lymphoblastic leukemia (T-ALL). It will also learn about the safety of the transplantation. The main questions it aims to answer are:\n\nDose co-infusion of cord blood in haploidentical hematopoietic cell transplantation (haplo-HCT) lower the rate of relapse? What medical problems do participants have when having haplo-cord HCT? Researchers will compare haplo-cord HCT to haplo-HCT to see if haplo-cord HCT works to treat T-ALL.\n\nParticipants will be infused an unrelated cord blood unit at the same day of haploidentical graft infusion.",[89,90,91],"Acute T Cell Lymphoblastic Leukemia","Haploidentical Hematopoietic Stem Cell Transplantation","Cord Blood","2024-04-24",{"date":94,"type":95},"2024-04-26","ACTUAL",{"date":97,"type":95},"2024-04-01",{"date":99,"type":83},"2028-03-31",{"name":5,"class":6},1]